Skip to main content
OpenTrials
Completed

NCT Number: NCT02987491

Exercise and Insulin Signaling in Human Skeletal Muscle

Obesity is associated with a decrease in skeletal muscle insulin sensitivity. Aerobic exercise can increase insulin sensitivity in the few hours following exercise, however the cellular mechanisms are not completely understood. The current project is to investigate mechanisms of exercise improvements to skeletal muscle insulin sensitivity.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–45 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Oregon State University

Corvallis, Oregon, 97331, United States

About this study

Study Overview: We are investigating the mechanisms by which exercise improves the response of skeletal muscle to insulin in lean and obese adults. Participants will complete 4 study visits consisting of: 1) screening visit, 2) maximal exercise test visit, and then a randomized order of 3) a resting metabolic study visit, and 4) an exercise metabolic study visit. Metabolic study visits for resting and exercise conditions will be identical, other than remaining sedentary or performing exercise. Skeletal muscle biopsy samples will be collected during resting, immediately post-exercise and during insulin stimulated conditions.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Males or Females
  • Aged 18-45 years
  • Normal weight (body mass index [BMI] 18-26 kg/m2) or obese (BMI 30-46 kg/m2)
  • Sedentary (< 1 hour of planned physical activity per week for ≥ 6 months)
  • Weight stable (< 2 kg change in body mass for ≥ 6 months)
  • Non-smokers (no tobacco or nicotine use for ≥ 1 year)

Exclusion criteria

  • Hypertension (systolic blood pressure >140 mmHg, diastolic blood pressure > 90mmHg)
  • Chronic health condition including diabetes, cardiovascular disease, treated hypertension, cancer, anemia, uncontrolled hyper- or hypothyroidism.
  • Pregnant, nursing, irregular menses or post-menopausal (if female)
  • Hyperglycemia (fasting glucose >126 mg/dl)
  • Hypercholesterolemia (fasting LDL>140mg/dl)
  • Hemoglobin < 13.0 g/dl (males), < 11.5 g/dl (females)
  • Compromised renal function (outside 135-145 mmol/L sodium, 3.5-5.1 mmol/L potassium)
  • Lidocaine allergy
  • Medications including β-blockers, angiotensin converting enzyme inhibitors, insulin, thiazolidinediones, metformin, sulfonylureas, chronic non-steroidal anti-inflammatory use, anti-coagulant (e.g. warfarin), current antibiotics, opiates, monoamine oxidase inhibitors, benzodiazepines, or others that may impact the study outcomes
  • Any physical limitation that prevents a participant from safely completing the exercise test
  • Due to the risks associated with the current protocol, individuals with a diminished capacity to consent will be excluded. Similarly, due to the need for constant, accurate participant monitoring during metabolic study activities, participants will need to clearly understand verbal and written English. Participants who cannot clearly understand verbal and written English will be excluded.

Treatment and study plan

Exercise

Behavioral

Participants will perform 2 metabolic study days of either resting or acute bout of cycling exercise in a randomized cross-over design.

Primary outcomes

  1. Skeletal muscle insulin sensitivity

    Time frame: 2 hours following rest or exercise

    Skeletal muscle insulin sensitivity will be measured by hyperinsulinemic-euglycemic clamp.

Sponsors and collaborators

Lead sponsor

Oregon State University

Other

Registry information

Important dates

Study start
2016
Primary completion
2018
Study completion
2018
First posted
Dec 9, 2016
Registry last updated
Aug 28, 2019

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.